137 related articles for article (PubMed ID: 33879671)
1. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
Zhang L; Liu Z; Zhu J
Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis.
Liu Q; Song X; Liu Z; Yu Z
Technol Cancer Res Treat; 2021; 20():15330338211019506. PubMed ID: 34184566
[TBL] [Abstract][Full Text] [Related]
3. miRNA-135b Contributes to
Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
[TBL] [Abstract][Full Text] [Related]
4. Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
Privat M; Rudewicz J; Sonnier N; Tamisier C; Ponelle-Chachuat F; Bignon YJ
Int J Med Sci; 2018; 15(1):46-58. PubMed ID: 29333087
[TBL] [Abstract][Full Text] [Related]
5. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
Zhong G; Lou W; Shen Q; Yu K; Zheng Y
Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
[TBL] [Abstract][Full Text] [Related]
6. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
7. A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer.
Liu Q; Wang Z; Kong X; Wang X; Qi Y; Gao R; Fang Y; Wang J
DNA Cell Biol; 2020 Apr; 39(4):671-682. PubMed ID: 32040341
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
[TBL] [Abstract][Full Text] [Related]
9. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
10. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE
Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800
[TBL] [Abstract][Full Text] [Related]
11. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma.
Liu J; Liao X; Zhu X; Lv P; Li R
Cancer Med; 2020 Oct; 9(19):7018-7033. PubMed ID: 32780509
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.
Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W
Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241
[TBL] [Abstract][Full Text] [Related]
16. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma.
Zhou JG; Zhao HT; Jin SH; Tian X; Ma H
Gynecol Oncol; 2019 Dec; 155(3):499-507. PubMed ID: 31662204
[TBL] [Abstract][Full Text] [Related]
17. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
[TBL] [Abstract][Full Text] [Related]
18. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
[TBL] [Abstract][Full Text] [Related]
20. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]